Ionis Pharmaceuticals Inc

IONS: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
cbnLOCK|%<zZwLOCK|bRP$<J

Ionis Earnings: Strong Commercial Launch of Tryngolza as Pipeline Advances; Shares Undervalued

Ionis' second quarter delivered $103 million in commercial revenue, including $19 million in sales for recently approved Tryngolza, for familial chylomicronemia syndrome. Management raised its 2025 revenue guidance by 14% at the midpoint, and shares traded up nearly 5% on July 30.

Sponsor Center